Company Encyclopedia
View More
name
Surmodics
SRDX.US
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets.
1.407 T
SRDX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking0/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-15.36%E
    • Profit Margin-14.59%D
    • Gross Margin45.38%B
  • Growth ScoreD
    • Revenue YoY-0.02%D
    • Net Profit YoY-1159.97%E
    • Total Assets YoY-4.28%D
    • Net Assets YoY-5.79%D
  • Cash ScoreD
    • Cash Flow Margin-685.32%E
    • OCF YoY-0.02%D
  • Operating ScoreB
    • Turnover0.7B
  • Debt ScoreB
    • Gearing Ratio34.46%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Surmodics to Delist Shares Following Merger Completion

    SurModics Inc. plans to delist its shares from Nasdaq following a merger completion on November 19, 2025. The company has requested a trading halt effective November 18, 2025, and filed for deregistration with the SEC, marking a significant change in its public reporting and trading status.

    Reuters·
    US
    SRDX
    0.00%
    Reuters·
    US
    SRDX
    0.00%

    Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today

    Surmodics, Inc. announced that the FTC and certain state regulators will not appeal the denial of an injunction to prevent the closing of its acquisition by GTCR LLC. The merger is expected to close promptly, subject to the expiration of a Temporary Restraining Order and other closing conditions. Surmodics is a provider of medical device and in vitro diagnostic technologies.

    fidelity·
    US
    SRDX
    0.00%
    fidelity·
    US
    SRDX
    0.00%

    SurModics Merger with GTCR LLC Clears Legal Hurdle

    SurModics, Inc. announced that the U.S. District Court for the Northern District of Illinois denied a request by the FTC to block its merger with GTCR LLC. This ruling is a significant step towards completing the merger, which SurModics believes will benefit its operations. However, the merger is still subject to a Temporary Restraining Order and other conditions. Analysts rate SRDX stock as a Hold with a $32.00 price target, while the company faces financial challenges, including declining revenues and profitability issues.

    Tip Ranks·
    US
    SRDX
    0.00%
    Tip Ranks·
    US
    SRDX
    0.00%

    Surmodics shares are trading higher after a US court reportedly denied the Federal Trade Commission's bid to block GTCR's acquisition of the company.

    benzinga_article·
    US
    SRDX
    0.00%
    benzinga_article·
    US
    SRDX
    0.00%

    Court Denies FTC Bid to Block Surmodics Acquisition by GTCR

    Surmodics, Inc. announced that the U.S. District Court for the Northern District of Illinois has denied the FTC's request to block its acquisition by GTCR LLC. However, the acquisition is still subject to a temporary restraining order that prevents closing before November 17, 5:00 p.m. Central time, along with other customary closing conditions. This court decision is a significant step forward for Surmodics in the acquisition process.

    Reuters·
    US
    SRDX
    0.00%
    Reuters·
    US
    SRDX
    0.00%
    © 2025 Longbridge｜Disclaimer